Cargando…
adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment
Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of ste...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229256/ https://www.ncbi.nlm.nih.gov/pubmed/34200614 http://dx.doi.org/10.3390/bioengineering8060083 |
_version_ | 1783712934711525376 |
---|---|
author | Kundu, Banani Brancato, Virginia Oliveira, Joaquim Correlo, Vitor M. Reis, Rui L. Kundu, Subhas C. |
author_facet | Kundu, Banani Brancato, Virginia Oliveira, Joaquim Correlo, Vitor M. Reis, Rui L. Kundu, Subhas C. |
author_sort | Kundu, Banani |
collection | PubMed |
description | Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of stem cells is reported to affect the proliferation and metastasis of osteosarcoma. Hence, the duo (osteosarcoma: Saos 2 and human adipose-derived stem cells: ASCs) is co-cultured in present study to investigate the therapeutic response using a nonadherent, concave surface. Staining with a cell tracker allows real-time microscopic monitoring of the cell arrangement within the sphere. Cell–cell interaction is investigated by means of E-cadherin expression. Comparatively high expression of E-cadherin and compact organization is observed in heterotypic tumorspheres (Saos 2–ASCs) compared to homotypic ones (ASCs), limiting the infiltration of chemotherapeutic compound doxorubicin into the heterotypic tumorsphere, which in turn protects cells from the toxic effect of the chemotherapeutic. In addition, genes known to be associated with drug resistance, such as SOX2, OCT4, and CD44 are overexpressed in heterotypic tumorspheres post-chemotherapy, indicating that the duo collectively repels the effect of doxorubicin. The interaction between ASCs and Saos 2 in the present study points toward the growing oncological risk of using ASC-based regenerative therapy in cancer patients and warrants further investigation. |
format | Online Article Text |
id | pubmed-8229256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82292562021-06-26 adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment Kundu, Banani Brancato, Virginia Oliveira, Joaquim Correlo, Vitor M. Reis, Rui L. Kundu, Subhas C. Bioengineering (Basel) Article Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of stem cells is reported to affect the proliferation and metastasis of osteosarcoma. Hence, the duo (osteosarcoma: Saos 2 and human adipose-derived stem cells: ASCs) is co-cultured in present study to investigate the therapeutic response using a nonadherent, concave surface. Staining with a cell tracker allows real-time microscopic monitoring of the cell arrangement within the sphere. Cell–cell interaction is investigated by means of E-cadherin expression. Comparatively high expression of E-cadherin and compact organization is observed in heterotypic tumorspheres (Saos 2–ASCs) compared to homotypic ones (ASCs), limiting the infiltration of chemotherapeutic compound doxorubicin into the heterotypic tumorsphere, which in turn protects cells from the toxic effect of the chemotherapeutic. In addition, genes known to be associated with drug resistance, such as SOX2, OCT4, and CD44 are overexpressed in heterotypic tumorspheres post-chemotherapy, indicating that the duo collectively repels the effect of doxorubicin. The interaction between ASCs and Saos 2 in the present study points toward the growing oncological risk of using ASC-based regenerative therapy in cancer patients and warrants further investigation. MDPI 2021-06-10 /pmc/articles/PMC8229256/ /pubmed/34200614 http://dx.doi.org/10.3390/bioengineering8060083 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kundu, Banani Brancato, Virginia Oliveira, Joaquim Correlo, Vitor M. Reis, Rui L. Kundu, Subhas C. adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment |
title | adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment |
title_full | adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment |
title_fullStr | adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment |
title_full_unstemmed | adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment |
title_short | adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment |
title_sort | adiposight in therapeutic response: consequences in osteosarcoma treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229256/ https://www.ncbi.nlm.nih.gov/pubmed/34200614 http://dx.doi.org/10.3390/bioengineering8060083 |
work_keys_str_mv | AT kundubanani adiposightintherapeuticresponseconsequencesinosteosarcomatreatment AT brancatovirginia adiposightintherapeuticresponseconsequencesinosteosarcomatreatment AT oliveirajoaquim adiposightintherapeuticresponseconsequencesinosteosarcomatreatment AT correlovitorm adiposightintherapeuticresponseconsequencesinosteosarcomatreatment AT reisruil adiposightintherapeuticresponseconsequencesinosteosarcomatreatment AT kundusubhasc adiposightintherapeuticresponseconsequencesinosteosarcomatreatment |